Y
Yves Chalandon
Researcher at University of Geneva
Publications - 278
Citations - 7560
Yves Chalandon is an academic researcher from University of Geneva. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 40, co-authored 238 publications receiving 6202 citations. Previous affiliations of Yves Chalandon include University of British Columbia & Geneva College.
Papers
More filters
Journal ArticleDOI
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Françoise Huguet,Thibaut Leguay,Emmanuel Raffoux,Xavier Thomas,Kheira Beldjord,Eric Delabesse,Patrice Chevallier,Agnès Buzyn,André Delannoy,Yves Chalandon,Jean-Paul Vernant,Marina Lafage-Pochitaloff,Agnès Chassevent,Véronique Lhéritier,Elizabeth Macintyre,Marie-Christine Béné,Norbert Ifrah,Hervé Dombret +17 more
TL;DR: It is suggested that pediatric-inspired therapy markedly improves the outcome of adult patients with ALL, at least until the age of 45 years, as compared with the previous LALA-94 experience.
Journal ArticleDOI
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn,Wim L.J. van Putten,Angèle Kelder,Vincent H.J. van der Velden,Rik A. Brooimans,Thomas Pabst,Johan Maertens,Nancy Boeckx,Georgine E. de Greef,Peter J. M. Valk,Frank Preijers,Peter C. Huijgens,Angelika M. Dräger,Urs Schanz,Mojca Jongen-Lavrecic,Bart J. Biemond,Jakob Passweg,Michel van Gelder,P. W. Wijermans,Carlos Graux,Mario Bargetzi,Marie-Cecile Legdeur,Jürgen Kuball,Okke de Weerdt,Yves Chalandon,Urs Hess,Leo F. Verdonck,Jan W. Gratama,Yvonne J M Oussoren,Willemijn J Scholten,J. Slomp,Alexander N Snel,Marie-Christiane Vekemans,Bob Löwenberg,Gert J. Ossenkoppele,Gerrit Jan Schuurhuis +35 more
TL;DR: The value of immunophenotypically assessed MRD in the context of a multicenter clinical trial in adult AML is established, based not only on risk estimation assessed at diagnosis but also on MRD as a therapy-dependent prognostic factor.
Journal ArticleDOI
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - Results of the GRAAPH-2003 study
Adrienne de Labarthe,Philippe Rousselot,Francoise Huguet-Rigal,Eric Delabesse,Francis Witz,Sébastien Maury,Delphine Rea,Jean-Michel Cayuela,M C Vekemans,Oumedaly Reman,Agnes Buzyn,Arnaud Pigneux,Martine Escoffre,Yves Chalandon,Elizabeth Macintyre,Véronique Lhéritier,Jean-Paul Vernant,Xavier Thomas,Norbert Ifrah,Hervé Dombret +19 more
TL;DR: This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context.
Journal ArticleDOI
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Yves Chalandon,Xavier Thomas,Sandrine Hayette,Jean-Michel Cayuela,Claire Abbal,Françoise Huguet,Emmanuel Raffoux,Thibaut Leguay,Philippe Rousselot,Stéphane Leprêtre,Martine Escoffre-Barbe,Sébastien Maury,Céline Berthon,Emmanuelle Tavernier,Jean-Francois Lambert,Marina Lafage-Pochitaloff,Véronique Lhéritier,Sylvie Chevret,Norbert Ifrah,Hervé Dombret +19 more
TL;DR: An induction regimen combining reduced-intensity chemotherapy and imatinib with allogeneic stem cell transplantation is validates and suggests that SCT in first CR is still a good option for Ph+ ALL adult patients.
Journal ArticleDOI
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Kheira Beldjord,Sylvie Chevret,Vahid Asnafi,Françoise Huguet,Marie-Laure Boulland,Thibaut Leguay,Xavier Thomas,Jean-Michel Cayuela,Nathalie Grardel,Yves Chalandon,Nicolas Boissel,Beat W. Schaefer,Eric Delabesse,Hélène Cavé,Patrice Chevallier,Agnes Buzyn,Thierry Fest,Oumedaly Reman,Jean-Paul Vernant,Véronique Lhéritier,Marie C. Béné,Marina Lafage,Elizabeth Macintyre,Norbert Ifrah,Hervé Dombret +24 more
TL;DR: It is indicated that genetic abnormalities are important predictors of outcome in adult ALL not fully recapitulated by early response to therapy, as assessed by immunoglobulin/T-cell receptor minimal residual disease (MRD) levels.